In a trial led by NUS, artificial intelligence platform CURATE.AI personalised treatment for a rare blood cancer patient by dynamically adjusting their drug dosages based on real-time responses. This AI-guided approach improved the patient’s condition while reducing costs and side effects by delivering precisely dosed medications through an evolving personalised profile.
